Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the recipient of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 3,829,755 shares, a decline of 4.1% from the May 15th total of 3,992,335 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average daily volume of 444,859 shares, the days-to-cover ratio is presently 8.6 days.
Several institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC lifted its holdings in shares of Synthetic Biologics by 312.1% in the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after purchasing an additional 183,120 shares during the last quarter. Virtu Financial LLC increased its position in Synthetic Biologics by 256.1% in the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock valued at $152,000 after acquiring an additional 215,440 shares during the period. Blair William & Co. IL increased its position in Synthetic Biologics by 14.8% in the 1st quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock valued at $631,000 after acquiring an additional 255,096 shares during the period. Finally, 683 Capital Management LLC acquired a new position in Synthetic Biologics in the 4th quarter valued at about $762,000.
Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Wednesday, March 14th. Griffin Securities lowered Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Synthetic Biologics in a report on Friday, May 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. Synthetic Biologics presently has a consensus rating of “Hold” and a consensus price target of $0.25.
Synthetic Biologics (NYSEAMERICAN:SYN) last issued its quarterly earnings data on Tuesday, May 8th. The company reported ($0.02) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.03.
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.